文献速递妇科

p53通路标志物进一步细化高危子宫内膜癌的分子分型:TransPORTEC研究

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
PubMed 文献 · Gynecol Oncol · 2017-05-13

研究分析114例高危子宫内膜癌(86例子宫内膜样、28例非子宫内膜样)中p53及下游标志物p21、mdm2、磷酸化p63(pp63)的免疫组化表达,并与临床结局关联;pp63或mdm2阳性与死亡风险显著增加相关(HR分别为5.93和7.48),这些发现在p53野生型和突变型肿瘤中均可见。

要点

  • 约半数高危子宫内膜癌呈p53突变表型,与p21表达呈强负相关。
  • pp63阳性或mdm2阳性与死亡可能性显著增加相关(HR 5.93和7.48)。
  • 上述关联在p53野生型和p53突变型肿瘤中均可见。

核心结论

  • p53通路标志物可改善子宫内膜癌的风险分层,并为该通路在疾病中的作用提供新见解。

研究设计与样本

  • 对114例具有高危特征(如高肿瘤分级和深肌层浸润)的子宫内膜癌(86例子宫内膜样、28例非子宫内膜样)进行免疫组化分析p53及下游标志物p21、mdm2和磷酸化p63(pp63)的表达,并与临床结局关联。
  • 利用癌症基因组图谱(TCGA)数据通过cBioPortal分析TP63突变和拷贝数改变。
  • 在两种子宫内膜癌细胞系中沉默TP53以研究其对p21和p63的影响。

主要发现

  • 约半数肿瘤显示p53突变表型,且与p21表达呈强负相关。
  • pp63阳性与死亡可能性显著增加相关,风险比5.93(95% CI 2.37-7.27)。
  • mdm2阳性与死亡可能性显著增加相关,风险比7.48(95% CI 3.04-9.39)。
  • 上述发现在p53野生型和p53突变型肿瘤中均可见。
  • TCGA子宫内膜癌中仅11%具有功能性TP63改变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway. METHODS: We analysed the expression of p53 as well as three downstream markers of the p53 pathway, p21, mdm2 and phospho-p63 (pp63), by immunohistochemistry in a series of 114 endometrial cancers (86 endometrioid, 28 non-endometrioid subtype) with high-risk features (such as high tumour grade and deep myometrial invasion) and correlated results with clinical outcome. The Cancer Genome Atlas (TCGA) data were used to analyse TP63 mutations and copy-number alterations using cBioPortal. TP53 was silenced in two endometrial cancer cell lines to study its effect on p21 and p63. RESULTS: About half of the tumours showed a p53 mutant phenotype and there was a strong negative correlation with p21 expression. Being marker positive for pp63 or mdm2 was associated with a significantly increased likelihood of dying, [hazard ratios 5.93 (95% CI 2.37-7.27) and 7.48 (95% CI 3.04-9.39), respectively]. These findings were seen in both p53 wildtype and p53 mutant tumours. Only 11% of TCGA endometrial cancers had a functional TP63 alteration. Upon silencing of TP53, p21 expression was decreased in one cell line, but no effects on p63 were observed. CONCLUSION: Markers of the p53 pathway improve stratification of endometrial cancers and provide novel insights into the role of this pathway in the disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, et al. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. Gynecol Oncol. 2017. PMID: 28511869. doi:10.1016/j.ygyno.2017.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。